Stock Ratings / Health Care / SLN / financials

OPK (39) SNDX (31) VSTM (24) LBRX (43) ⌘ Pro Terminal →

Silence Therapeutics Plc American Depository Share (SLN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$19.80 +0.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.78

Silence Therapeutics Plc American Depository Share (SLN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.23B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $19.78 (-0.11%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLN)Realized 20D OHLCV Swing Band: ±8%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY SLN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 34.4% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.86-12% Next Q

Q2 (-2Q)

Grade E$8.68+126.6% Next Q

Q3 (-1Q)

Grade E$19.67+0.7% Next Q

Current

Grade E$19.80-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLN currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.48) and Max Pain ($20.79) forces dealer call-delta covering toward $20.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SLN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $31.6M

FY24

Rev $43.3M

FY25

Rev $559.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$559.0K	61.5%	-80%	-$88.6M	-$62.3M	-45%
FY 2024	$43.3M	72.7%	-80%	-$45.3M	-$67.9M	-45%
FY 2023	$31.6M	61.5%	-80%	-$54.2M	-$49.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLN)

✓Walkthrough of SLN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +170.86%⚡ TESTING RESISTANCE

2026-10-30O $19.74H $19.80L $19.74C $19.80VOL 621.4K

RES: $20.03SUP: $8.35SMA50: $13.48SMA200: $9.06

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLN Butterfly Map → + Track SLN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLN)

Health Care Rank #836 of 1016 ⚔️ OPK vs SLN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLN vs. OPK, SNDX, VSTM, LBRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Silence Therapeutics Plc American Depository Share (SLN) ranks #836 by composite RQD confidence (34/100, grade E) and #336 by equity capitalization ($1.23B). Within this direct 5-issuer industry benchmark cohort, SLN leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. LBRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SLN at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLN ACTIVE Silence Therapeutics Plc American Depository Share	E	34/100	—	61.5%	-35.0%	+0.46%	$1.23B	Benchmark Subject
OPK OPKO Health Inc.	D-	39/100	—	33.9%	-10.2%	+2.47%	$1.24B	/opk-vs-sln →
SNDX Syndax Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.19%	$1.26B	/sndx-vs-sln →
VSTM Verastem Inc.	E	24/100	—	—	-35.0%	-1.78%	$1.17B	/vstm-vs-sln →
LBRX LB Pharmaceuticals Inc	D-	43/100	—	—	-8.4%	+0.80%	$1.30B	/lbrx-vs-sln →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001479615

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Silence Therapeutics Plc American Depository Share (SLN) reported GAAP revenue of $559.0K (-98.7% vs. FY2024 revenue of $43.3M , and -98.2% cumulative change since FY2023) , GAAP net income of -$88.6M, operating cash flow of -$62.3M, and free cash flow of -$62.3M (+8.1% YoY). On the balance sheet, SLN closed FY2025 with $131.4M in total assets against $0 in total debt (Altman Z-Score: 3.36, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$559.0K	-$88.6M	-$62.3M	-$62.3M	$131.4M	—
FY2024 (FY)	2024-12-31	$43.3M	-$45.3M	-$67.6M	-$67.9M	$202.6M	—
FY2023 (FY)	2023-12-31	$31.6M	-$54.2M	-$49.5M	-$49.5M	—	—

3. SLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Silence Therapeutics Plc American Depository Share (NASDAQ: SLN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $19.80 (+0.46% 1D, market cap $1.23B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLN ranks #836 in composite RQD confidence.

How does SLN compare to OPK and SNDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 61.5%, and ROIC of -35.0%. By comparison, OPK (OPKO Health Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B) and SNDX (Syndax Pharmaceuticals Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.26B). Among the 5-stock peer group, SLN leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLN?

Per SLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479615), Silence Therapeutics Plc American Depository Share generated $559.0K in revenue (-98.7% YoY), -$88.6M in net income, and -$62.3M in free cash flow against $131.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLN trading relative to its 50-day, 200-day, and 52-week technical levels?

SLN last traded at $19.80 (+0.46% on volume of 1,814,688 shares), positioning the stock +46.88% above its 50-day simple moving average ($13.48) and +118.54% above its 200-day simple moving average ($9.06). Across its 52-week range of $4.19 to $19.86, SLN sits at the 99.6% percentile with a 14-day RSI of 78.9 (OVERBOUGHT (>70)) and an implied next-earnings move of ±8.0% ($18.22 to $21.38).

SLN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Silence Therapeutics Plc American Depository Share (SLN)?

In FY 2025 (10-K), SLN converted $1.0M of revenue into a 34.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SLN RQD Cockpit SLN 12M Forecast SLN Earnings & Move SLN Dividends & DRIP SLN Insiders & 13F SLN Whale Options SLN Profit Sankey SLN News & Why